NBIX - Neurocrine Biosciences, Inc.
| Previous Close | 92.49 |
| Open | 92.52 |
| Bid | 89.00 x 800 |
| Ask | 99.00 x 800 |
| Day's Range | 91.68 - 93.72 |
| 52 Week Range | 41.76 - 94.48 |
| Volume | 500,268 |
| Avg. Volume | 778,793 |
| Market Cap | 8.383B |
| Beta | 2.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.62 |
| Earnings Date | Aug 1, 2018 - Aug 6, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1995-12-29 |
| 1y Target Est | 110.64 |
- TheStreet.com•6 days ago
5 Stocks That Are Screaming Buys Right Now
Here we used TipRanks' stock screener to pinpoint the most compelling stocks right now. The Street is buzzing about Neurocrine's Ingrezza drug, the first FDA-approved treatment for adults with tardive dyskinesia. On its first quarter earnings call, Neurocrine updated the Street with respect to ongoing market penetration for Ingrezza.
- GlobeNewswire•7 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Fred's, Nexstar Broadcasting Group, CNO Financial Group, Neurocrine Biosciences, Kosmos Energy, and Loews — New Research Emphasizes Economic Growth
NEW YORK, May 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fred's, ...
- PR Newswire•12 days ago
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
Live Audio Webcast Will be on May 15, 2018 SAN DIEGO , May 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch 2018 Healthcare Conference ...
- Motley Fool•12 days ago
3 Top Biotech Stocks to Buy in May
Looking for a few timely buys in the biotech space? Give these gems a closer look.
- PR Newswire•13 days ago
Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics
SAN DIEGO, May 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), providing valuable insight into the impact of involuntary movements on the quality of life of patients taking antipsychotic medication. TD is a condition that is characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face, which may be disruptive and negatively impact patients.
- Zacks Small Cap Research•18 days ago
NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth
By David Bautz, PhD NASDAQ:NBIX INGREZZA® Launch Continues to go Well On April 30, 2018, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced financial results for the first quarter of 2018 and provided ...
- PR Newswire•19 days ago
Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting
SAN DIEGO, May 2, 2018 /PRNewswire/ -- Neurocrine Biosciences Inc. (NBIX) today announced that it will present new data from RE-KINECT, the largest real-world screening study to date of patients with clinician confirmed possible tardive dyskinesia (TD). This study is designed to better understand the potentially broad reaching impact of symptoms of possible TD on patients treated with antipsychotic medications.
- Thomson Reuters StreetEvents•19 days ago
Edited Transcript of NBIX earnings conference call or presentation 30-Apr-18 9:00pm GMT
Q1 2018 Neurocrine Biosciences Inc Earnings Call
- Benzinga•20 days ago
Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 30) CareDx Inc (NASDAQ: CDNA ) Eleven Biotherapeutics Inc (NASDAQ: ...
- Associated Press•21 days ago
Neurocrine: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 47 cents. The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...
- PR Newswire•21 days ago
Neurocrine Biosciences Reports First Quarter 2018 Financial Results
INGREZZA® (valbenazine) First Quarter Net Product Sales of $71.1 Million with Approximately 12,500 TRx Strong INGREZZA Demand Leads to Expansion of Sales Force Increased Investment in Tourette Syndrome ...
- ACCESSWIRE•21 days ago
Neurocrine Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 30, 2018 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 30, 2018 at 5:00 PM Eastern ...
- PR Newswire•24 days ago
AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
- Seven presentations of elagolix data highlight AbbVie's research in endometriosis and uterine fibroids - Primary and secondary efficacy and safety data to be presented from two extension Phase 3 studies ...
Market Realist•25 days agoWhat Analysts Recommend for Neurocrine Biosciences in April 2018
In April 2018, the US FDA (Food and Drug Administration) notified Neurocrine Biosciences and AbbVie (ABBV) that it would require more time to review additional information associated with the liver function tests provided by AbbVie in addition to it its NDA (new drug application) for Elagolix. The US FDA granted the new PDUFA (Prescription Drug Fee User Act) action date in 3Q18.
Market Realist•25 days agoHow Neurocrine Biosciences Is Positioned ahead of 1Q18 Earnings
How Neurocrine Biosciences Is Positioned ahead of 1Q18 EarningsNeurocrine Biosciences revenue trends
- PR Newswire•26 days ago
Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions
Additional Long-Term Data Show INGREZZA Sustained Improvement of Tardive Dyskinesia Symptoms Through 48 Weeks of Treatment and was Well-Tolerated SAN DIEGO , April 25, 2018 /PRNewswire/ -- Neurocrine Biosciences, ...
- PR Newswire•28 days ago
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results
Conference Call and Webcast Scheduled for Monday, April 30 SAN DIEGO , April 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report first quarter financial ...
- PR Newswire•last month
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , April 19, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
- PR Newswire•last month
Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting
SAN DIEGO, April 18, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that new data for once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), will be presented at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles, Calif., April 21-27, 2018. Highlighted presentations include analysis of the short- and long-term effects of INGREZZA on TD symptoms by body region, long-term INGREZZA safety and efficacy data from the KINECT 4 Phase III open-label study and data from RE-KINECT, a real-world screening study of patients with possible TD. "The symptoms of tardive dyskinesia are heterogeneous, with each patient experiencing tardive dyskinesia somewhat differently.
Market Realist•last monthIngrezza: Boosting Neurocrine’s Top Line
Neurocrine Biosciences (NBIX) is a pharmaceutical company with a focus on neurological and endocrine-based diseases and disorders. Its leading product on the market is Ingrezza, a vesicular monoamine transporter 2 (or VMAT2) inhibitor used in the treatment of movement disorders. Ingrezza was approved by the FDA for the treatment of tardive dyskinesia (or TD) in April 2017.
- Reuters•last month
FDA needs more time to review AbbVie, Neurocrine's uterine pain drug
AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug. The agency requested more time to review additional information regarding the results of liver function tests provided by AbbVie in connection with the application for Elagolix in endometriosis-associated pain, the companies said.
- Reuters•last month
FDA extends review for AbbVie, Neurocrine's uterine pain drug
AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug. The agency requested more time to review additional information regarding the results of liver function tests provided by AbbVie in connection with the application for Elagolix in endometriosis-associated pain, the companies said. The FDA is now expected to make its decision in the third quarter of 2018, three months later than initially expected.
- PR Newswire•last month
AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
- FDA requires extended time for review of additional information in New Drug Application (NDA) - Elagolix clinical trial program largest prospective randomized endometriosis trial conducted to date - ...
- Forbes•last month
A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star
Who's the world's best hedge fund manager? David Tepper? Stevie Cohen? Try Joe Edelman, a wannabe psychologist with a bead on biotech who has quietly built the best track record of the past two decades.
Markit•last monthSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
